No results for ‘’
Gufic BioSciences Ltd
₹355.25
(0.67%)
Thu, 25 Jun 2026, 06:22 am
Health Technology
Pharmaceuticals: Major
24.5KGufic BioSciences Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 36.26 | 105.22 | 92.18 | 30.45 | 41.12 | 30.42 | 26.55 | 14.81 | 9.35 | 23.93 | 44.11 | 56.71 | 51.13 | 26.98 | 20.15 | 25.05 | 25.18 | 22.70 | 32.39 | 48.44 |
| Price to book ratio | 6.12 | 4.62 | 4.82 | 1.56 | 2.92 | 2.42 | 2.10 | 2.21 | 1.52 | 3.70 | 9.58 | 13.80 | 15.56 | 7.86 | 3.53 | 6.39 | 8.97 | 5.20 | 5.33 | 5.61 |
| Price to sales ratio | 1.62 | 1.37 | 1.47 | 0.50 | 0.83 | 0.64 | 0.51 | 0.50 | 0.33 | 0.67 | 1.61 | 2.09 | 2.76 | 1.69 | 1.21 | 2.27 | 3.10 | 2.62 | 3.46 | 4.12 |
| Price to cash flow ratio | 16.77 | 15.19 | 0 | 9.86 | 31.97 | 0 | 16.11 | 32.42 | 5.63 | 14.69 | 0 | 0 | 0 | 0 | 13.05 | 14.36 | 23.93 | 0 | 0 | 32.88 |
| Enterprise value | 117Cr | 91.48Cr | 93.44Cr | 40.56Cr | 67.33Cr | 63.3Cr | 60.53Cr | 82.82Cr | 65.7Cr | 127Cr | 361Cr | 564Cr | 915Cr | 682Cr | 567Cr | 1156Cr | 2451Cr | 2097Cr | 3109Cr | 3681Cr |
| Enterprise value to EBITDA ratio | 16.85 | 19.42 | 25.69 | 7.59 | 12.96 | 10.13 | 8.69 | 7.53 | 5.50 | 8.79 | 17.68 | 24.42 | 23.40 | 14.71 | 10.51 | 13.64 | 16.72 | 14.99 | 20.73 | 26.24 |
| Debt to equity ratio | 1.47 | 1.18 | 1.01 | 0.91 | 1.01 | 1.06 | 1.05 | 1.56 | 1.28 | 1.22 | 1.26 | 1.52 | 1.47 | 1.30 | 0.98 | 0.35 | 0.24 | 0.96 | 0.63 | 0.56 |
| Return on equity % | 0 | 4.37 | 5.46 | 5.08 | 7.21 | 8.17 | 8.05 | 15.94 | 17.64 | 15.67 | 24.09 | 25.40 | 36.08 | 34.09 | 22.17 | 32.85 | 43.31 | 25.84 | 19.57 | 12.29 |
Gufic BioSciences Ltd Enterprise Value
The Gufic BioSciences Ltd Enterprise Value is a key financial metric used by investors to evaluate Gufic BioSciences Ltd's valuation, profitability, and overall financial performance. Tracking the Gufic BioSciences Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Gufic BioSciences Ltd (NSE: GUFICBIO, BSE: 509079) is currently trading at ₹355.25, with a market capitalization of ₹3570.06Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Gufic BioSciences Ltd Enterprise Value is essential for fundamental analysis.
Gufic BioSciences Ltd Enterprise Value Current Value
The current Gufic BioSciences Ltd Enterprise Value stands at 3681Cr.
The latest Gufic BioSciences Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Gufic BioSciences Ltd Enterprise Value Historical Trend
The Gufic BioSciences Ltd Enterprise Value has shown the following historical trend:
- 2024: 3681Cr
- 2023: 3109Cr
- 2022: 2097Cr
- 2021: 2451Cr
- 2020: 1156Cr
The recent rise in Gufic BioSciences Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Gufic BioSciences Ltd Enterprise Value Indicates for Investors
The Gufic BioSciences Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Gufic BioSciences Ltd.
Gufic BioSciences Ltd Enterprise Value Analysis Summary
The Gufic BioSciences Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Gufic BioSciences Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Gufic BioSciences Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.